Literature DB >> 28090532

Afatinib for patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: clinical implications of the LUX-Lung 7 study.

Keunchil Park1.   

Abstract

Entities:  

Year:  2016        PMID： 28090532      PMCID： PMC5220032          DOI： 10.21037/atm.2016.11.42

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  3 in total

1.  First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.

Authors:  Y-L Wu; C Zhou; C-K Liam; G Wu; X Liu; Z Zhong; S Lu; Y Cheng; B Han; L Chen; C Huang; S Qin; Y Zhu; H Pan; H Liang; E Li; G Jiang; S H How; M C L Fernando; Y Zhang; F Xia; Y Zuo
Journal:  Ann Oncol       Date:  2015-06-23       Impact factor: 32.976

2.  Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.

Authors:  Keunchil Park; Eng-Huat Tan; Ken O'Byrne; Li Zhang; Michael Boyer; Tony Mok; Vera Hirsh; James Chih-Hsin Yang; Ki Hyeong Lee; Shun Lu; Yuankai Shi; Sang-We Kim; Janessa Laskin; Dong-Wan Kim; Catherine Dubos Arvis; Karl Kölbeck; Scott A Laurie; Chun-Ming Tsai; Mehdi Shahidi; Miyoung Kim; Dan Massey; Victoria Zazulina; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2016-04-12       Impact factor: 41.316

Review 3.  Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.

Authors:  Erin L Stewart; Samuel Zhixing Tan; Geoffrey Liu; Ming-Sound Tsao
Journal:  Transl Lung Cancer Res       Date:  2015-02
  3 in total
  1 in total

Review 1.  Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors.

Authors:  Vera Hirsh
Journal:  Ther Adv Med Oncol       Date:  2018-01-22       Impact factor: 8.168
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.